The DESTINY-Breast06 trial (NCT04494425), a randomized, multicenter, open-label study, further supported the expanded 2025 approval by demonstrating a mPFS of 13.2 months with T-DXd versus 8.1 months with chemotherapy (HR 0.62, 95% CI: 0.52–0.75; p < 0.0001) in patients with HER2-low breast cancer (n = 713) [102]. Here, ERBB2 is linked to breast carcinoma.